These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
28. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Hong YS; Nam BH; Kim KP; Kim JE; Park SJ; Park YS; Park JO; Kim SY; Kim TY; Kim JH; Ahn JB; Lim SB; Yu CS; Kim JC; Yun SH; Kim JH; Park JH; Park HC; Jung KH; Kim TW Lancet Oncol; 2014 Oct; 15(11):1245-53. PubMed ID: 25201358 [TBL] [Abstract][Full Text] [Related]
29. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442 [TBL] [Abstract][Full Text] [Related]
30. What options are available for refractory pancreatic cancer? Choi M; Kim R; Saif MW JOP; 2012 Mar; 13(2):163-5. PubMed ID: 22406591 [TBL] [Abstract][Full Text] [Related]
31. A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: a Hellenic Cooperative Oncology Group study. Papadimitriou CA; Papakostas P; Karina M; Malettou L; Dimopoulos MA; Pentheroudakis G; Samantas E; Bamias A; Miliaras D; Basdanis G; Xiros N; Klouvas G; Bafaloukos D; Kafiri G; Papaspirou I; Pectasides D; Karanikiotis C; Economopoulos T; Efstratiou I; Korantzis I; Pisanidis N; Makatsoris T; Matsiakou F; Aravantinos G; Kalofonos HP; Fountzilas G BMC Med; 2011 Jan; 9():10. PubMed ID: 21281463 [TBL] [Abstract][Full Text] [Related]
32. Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma. Cantore M; Serio G; Pederzoli P; Mambrini A; Iacono C; Pulica C; Capelli P; Lombardi M; Torri T; Pacetti P; Pagani M; Fiorentini G Cancer Chemother Pharmacol; 2006 Oct; 58(4):504-8. PubMed ID: 16633830 [TBL] [Abstract][Full Text] [Related]
33. Adjuvant FOLFOX+Nab-Paclitaxel (FOLFOX-A) for Pancreatic Cancer: A Brown University Oncology Research Group Phase II Study (BrUOG295). Raufi AG; Breakstone R; Leonard K; Charpentier K; Beard R; Renaud J; Cavanaugh L; Sturtevant A; MacKinnon K; Almhanna K; Olszewski A; Safran HP Am J Clin Oncol; 2020 Dec; 43(12):857-860. PubMed ID: 32976178 [TBL] [Abstract][Full Text] [Related]
34. Modified FOLFIRINOX versus sequential chemotherapy (FOLFIRI/FOLFOX) as a second-line treatment regimen for unresectable pancreatic cancer: A real-world analysis. Tezuka S; Ueno M; Oishi R; Nagashima S; Sano Y; Kawano K; Tanaka S; Fukushima T; Asama H; Konno N; Kobayashi S; Morimoto M; Maeda S Cancer Med; 2022 Feb; 11(4):1088-1098. PubMed ID: 34953056 [TBL] [Abstract][Full Text] [Related]
36. Pancreatic cancer in 2010: new insights for early intervention and detection. Costello E; Neoptolemos JP Nat Rev Gastroenterol Hepatol; 2011 Feb; 8(2):71-3. PubMed ID: 21293504 [TBL] [Abstract][Full Text] [Related]
37. A UGT1A1 genotype-guided dosing study of modified FOLFIRINOX in previously untreated patients with advanced gastrointestinal malignancies. Sharma MR; Joshi SS; Karrison TG; Allen K; Suh G; Marsh R; Kozloff MF; Polite BN; Catenacci DVT; Kindler HL Cancer; 2019 May; 125(10):1629-1636. PubMed ID: 30645764 [TBL] [Abstract][Full Text] [Related]
38. Pancreatic metastasis from colon carcinoma treated with radiotherapy with palliative benefit. Saif MW; Kaley K JOP; 2010 Nov; 11(6):644-5; author reply 650. PubMed ID: 21068505 [No Abstract] [Full Text] [Related]
39. Selecting chemotherapy for pancreatic cancer: Far away or so close? Shi S; Yu X Semin Oncol; 2019 Feb; 46(1):39-47. PubMed ID: 30611527 [TBL] [Abstract][Full Text] [Related]